Forbes spotlights 30 healthcare innovators under 30

Amy Baxter | | Health Exec | Management

Forbes released its annual 30 under 30 list, spotlighting entrepreneurs, leaders and stars across 20 different industries, including healthcare.

Those on the healthcare list include capitalists investing in therapeutics, researchers looking for ways to improve diagnostic tests through CRISPR technology and entrepreneurs seeking to diagnose symptoms through telehealth.

Others are looking at stem cell therapies, cancer detection, easing the bottleneck of experimental drug testing and how to equip Africa with digital technology in healthcare.

The seventh Forbes 30 under 30 list featured 600 individuals. Nominations were vetted by a panel of judges and reporters.

See the full healthcare list below:

The 2019 30 Under 30

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

DEA wants to permanently anchor some COVID-era prescription regulations
Sesame Street is coming to NewYork-Presbyterian Hospital
Q&A: Vulnerable patients hit hardest by anesthesia reimbursement cuts
Hospital sued for $900K after man’s face ignites during surgery
Dental chain involved in ransomware coverup fined $350K
Healthcare, AI top list of fastest growing jobs

Around the web

AI in Healthcare
Nat’l Academy of Medicine sets ‘priorities for action’ as healthcare mulls next moves with AI

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

Cardiovascular Business
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.